



FOR IMMEDIATE RELEASE

**June 28<sup>th</sup>, 2021**

**Anwita Biosciences, Inc. Completes \$18.5 Million Series B Financing to Advance Its Improved Cytokines (Exenokines) And Tumor Targeting Antibody Drug Conjugates**

- Proceeds will further advance discovery research and accelerate the path toward clinical development.
- Financing led by Shanghai Junshi Biosciences Co., Ltd. with participation from Hong Kong Ruihua Investment Management Limited and GQCR Capital Management LLP.

SAN CARLOS, California, June 28, 2021 – Anwita Biosciences, Inc. (“Anwita”), a privately-held biotechnology company dedicated to advance its improved Cytokines (Exenokines) and tumor targeting antibody drug conjugates, today announced the successful completion of a \$18.5 million Series B financing.

The financing was led by Shanghai Junshi Biosciences Co., Ltd. with participation from new investors Hong Kong Ruihua Investment Management Limited and GQCR Capital Management LLP.

Proceeds from the financing will be used to advance Anwita’s pipeline and accelerate the path toward clinical development. Anwita will accelerate its pace for the development of its lead programs (Exenokine-21, Exenokine-2, and Mableukin-2PD1), and will continue to deploy its patented platform technology to accelerate development of a diversified portfolio of cytokine-based products with improved pharmaceutical properties.

"We are pleased to have such strong support from outstanding investors," said Ziyang Zhong, President & CEO of Anwita Biosciences, Inc. "Their commitment is a testament to the potential of the Company's platform and pipeline. This investment will allow us to advance our research and a growing pipeline to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases."

**About Anwita Biosciences, Inc.**

Anwita Biosciences, Inc. is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area. Our mission is to deliver transformative treatment options to improve the

lives of patients with cancer and autoimmune diseases. Anwita specializes in the discovery and development of optimized immunotherapeutics, leveraging its core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering.

### **Investor Relations**

Contact: Investor Relations

Telephone: (650) 600-9828

Email: [contact@anwitabio.com](mailto:contact@anwitabio.com)

Website: [www.anwitabio.com](http://www.anwitabio.com)